{"id":"W2966320079","doi":"10.1200/jco.2012.30.15_suppl.tps4686","title":"A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Oncology; Renal cell carcinoma; Clear cell renal cell carcinoma; Biomarker; Phases of clinical research; Clinical trial; Urology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088132,0.001420862,0.001501046,0.000260532,0.0002943349,0.001082853,0.0005906761,0.000903149,0.003991531],"category_scores_gemma":[0.0007002829,0.0004670962,0.0007350214,0.0003383939,0.0005447496,0.0006790672,0.0004122462,0.002088918,0.001099214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001492432,"about_ca_system_score_gemma":0.001533151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001558491,"about_ca_topic_score_gemma":0.005516256,"domain_scores_codex":[0.9996101,0.0002151158,0.00001162946,0.00006442295,0.00003720927,0.00006150694],"domain_scores_gemma":[0.9994903,0.00004613402,0.0001322831,0.00003106296,0.00003951595,0.0002606593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8565694,0.02616271,0.01734228,0.0005970757,0.0009728335,0.0001513886,0.0002373363,0.002120452,0.02791363,0.0003276074,0.006180644,0.06142461],"study_design_scores_gemma":[0.6694568,0.2832701,0.03344911,0.0000417611,0.0007602368,0.000344581,0.0001154424,0.002500622,0.003148342,0.0003352078,0.006534413,0.00004342674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927276,0.001441803,0.0002257304,0.0005541865,0.000105295,0.00149104,0.001174247,0.000076248,0.002203812],"genre_scores_gemma":[0.9860765,0.001341249,0.001325343,0.0008617611,0.00013255,0.002175328,0.004185251,0.00002623586,0.00387569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003991531,"threshold_uncertainty_score":0.01335305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139575818884972,"score_gpt":0.4742149393619131,"score_spread":0.3602573574734159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}